Idiopathic pulmonary fibrosis is a condition in which the tissues in the lungs become thick and stiff over time. As a result of thickening of lung tissues, brain and other organs are unable receive optimum oxygen. Research Beam Model: Research Beam Product ID: 2139704 5370 USD New
Idiopathic Pulmonary Fibrosis Market by Type of Drug (Pirfenidone, Nintedanib) and Region (North America, Europe, Asia-Pacific, and LAMEA) - Global Opportunity Analysis and Industry Forecast, 2017-2023

Toll Free : +1 (800)910-6452

 
 
PURCHASE OPTIONS
 

Idiopathic Pulmonary Fibrosis Market by Type of Drug (Pirfenidone, Nintedanib) and Region (North America, Europe, Asia-Pacific, and LAMEA) - Global Opportunity Analysis and Industry Forecast, 2017-2023

 
  • Category : Medical Devices
  • Published On : September  2017
  • Pages : 150
 
 

Idiopathic pulmonary fibrosis is a condition in which the tissues in the lungs become thick and stiff over time. As a result of thickening of lung tissues, brain and other organs are unable receive optimum oxygen.

The global idiopathic pulmonary fibrosis market generated $1,616 million in 2016, and is projected to reach $3,569 million by 2023, registering a CAGR of 11.9% during the study period. The major factors that drive the growth of the global idiopathic pulmonary fibrosis market include rise in prevalence of fibrotic disease and increase in geriatric population. In addition, surge in demand for cost-effective drugs and introduction of advanced treatment options propel the market growth. However, unavailability of the proper treatment options of the disease restricts the market growth.

The global idiopathic pulmonary fibrosis market is segmented on the basis of type of drug and region. According to type of drug, the market is divided into pirfenidone and nintedanib. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

  • The report provides an in-depth analysis of parent market trends, macro-economic indicators, and governing factors.
  • This report provides an extensive analysis of the current and emerging market trends and dynamics in the market from 2016 to 2023 that helps identify the upcoming market opportunities.
  • Recent industry trends and developments and the future opportunities are also covered.
  • Extensive knowledge about the key market players and their strategies is provided.
  • Comprehensive analysis of the various factors that drive and restrain the growth of the market is provided.

Key Market Segments

By Type of Drug

  • Pirfenidone
  • Nintedanib

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key market players

  • The key players operating in this market include
  • MediciNova, Inc.
  • Boehringer Ingelheim
  • F. Hoffmann-La Roche
  • FibroGen, Inc.
  • Promedior, Inc.
  • Merck & Co., Inc.
  • Galapagos NV
  • Biogen
  • Bristol-Myers Squibb Company
  • Prometic Life Sciences Inc.
  • Cipla Inc.

CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top winning strategies
3.2.2. Top investment pockets

3.3. MARKET SHARE ANALYSIS, 2016
3.4. MARKET DYNAMICS

3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.4.4. Impact analysis

CHAPTER 4 GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. PIRFENIDONE

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. NINTEDANIB

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

CHAPTER 5 IDIOPATHIC PULMONARY FIBROSIS MARKET, BY REGION

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. NORTH AMERICA

5.2.1. Key market trends
5.2.2. Key growth factors and opportunities
5.2.3. Market size and forecast
5.2.4. U.S.
5.2.5. Canada
5.2.6. Mexico

5.3. EUROPE

5.3.1. Key market trends
5.3.2. Key growth factors and opportunities
5.3.3. Market size and forecast
5.3.4. Germany
5.3.5. France
5.3.6. UK
5.3.7. Italy
5.3.8. Spain
5.3.9. Rest of Europe

5.4. ASIA-PACFIC

5.4.1. Key market trends
5.4.2. Key growth factors and opportunities
5.4.3. Market size and forecast
5.4.4. Japan
5.4.5. China
5.4.6. India
5.4.7. South Korea
5.4.8. Rest of Asia-Pacific

5.5. LAMEA

5.5.1. Key market trends
5.5.2. Key growth factors and opportunities
5.5.3. Market size and forecast
5.5.4. Brazil
5.5.5. South Africa
5.5.6. Saudi Arabia
5.5.7. Rest of LAMEA

CHAPTER 6 COMPANY PROFILES

6.1. MEDICINOVA, INC.

6.1.1. Company overview
6.1.2. Operating business segments
6.1.3. Business performance
6.1.4. Key strategic moves and developments

6.2. BOEHRINGER INGELHEIM

6.2.1. Company overview
6.2.2. Operating business segments
6.2.3. Business performance
6.2.4. Key strategic moves and developments

6.3. F. HOFFMANN-LA ROCHE

6.3.1. Company overview
6.3.2. Operating business segments
6.3.3. Business performance
6.3.4. Key strategic moves and developments

6.4. FIBROGEN, INC.

6.4.1. Company overview
6.4.2. Operating business segments
6.4.3. Business performance
6.4.4. Key strategic moves and developments

6.5. PROMEDIOR, INC.

6.5.1. Company overview
6.5.2. Operating business segments
6.5.3. Business performance
6.5.4. Key strategic moves and developments

6.6. MERCK & CO., INC.

6.6.1. Company overview
6.6.2. Operating business segments
6.6.3. Business performance
6.6.4. Key strategic moves and developments

6.7. GALAPAGOS NV

6.7.1. Company overview
6.7.2. Operating business segments
6.7.3. Business performance
6.7.4. Key strategic moves and developments

6.8. BIOGEN

6.8.1. Company overview
6.8.2. Operating business segments
6.8.3. Business performance
6.8.4. Key strategic moves and developments

6.9. BRISTOL-MYERS SQUIBB COMPANY

6.9.1. Company overview
6.9.2. Operating business segments
6.9.3. Business performance
6.9.4. Key strategic moves and developments

6.10. PROMETIC LIFE SCIENCES INC.

6.10.1. Company overview
6.10.2. Operating business segments
6.10.3. Business performance
6.10.4. Key strategic moves and developments

6.11. CIPLA INC.

6.11.1. Company overview
6.11.2. Operating business segments
6.11.3. Business performance
6.11.4. Key strategic moves and developments

LIST OF TABLES

TABLE 1. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 2. PIRFENIDONE MARKET, BY REGION, 2016-2023, ($MILLION)
TABLE 3. PIRFENIDONE MARKET, BY COUNTRY, 2016-2023, ($MILLION)
TABLE 4. NINTEDANIB MARKET, BY REGION, 2016-2023, ($MILLION)
TABLE 5. NINTEDANIB MARKET, BY COUNTRY, 2016-2023, ($MILLION)
TABLE 6. IDIOPATHIC PULMONARY FIBROSIS MARKET, BY REGION, 2016-2023, ($MILLION)
TABLE 7. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY COUNTRY, 2016-2023, ($MILLION)
TABLE 8. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 9. U.S. IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 10. CANADA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 11. MEXICO IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 12. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET, BY COUNTRY, 2016-2023, ($MILLION)
TABLE 13. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 14. GERMANY IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 15. FRANCE IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 16. UK IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 17. ITALY IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 18. SPAIN IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 19. REST OF EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 20. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET, BY COUNTRY, 2016-2023, ($MILLION)
TABLE 21. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 22. JAPAN IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 23. CHINA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 24. INDIA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 25. SOUTH KOREA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 26. REST OF ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 27. LAMEA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY COUNTRY, 2016-2023, ($MILLION)
TABLE 28. LAMEA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE, 2016-2023, ($MILLION)
TABLE 29. BRAZIL IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 30. SOUTH AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 31. SAUDI ARABIA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 32. REST OF LAMEA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY TYPE OF DRUG, 2016-2023, ($MILLION)
TABLE 33. MEDICINOVA, INC.: COMPANY SNAPSHOT
TABLE 34. BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
TABLE 35. ROCHE: COMPANY SNAPSHOT
TABLE 36. FIBROGEN: COMPANY SNAPSHOT
TABLE 37. PROMEDIOR: COMPANY SNAPSHOT
TABLE 38. MERCK: COMPANY SNAPSHOT
TABLE 39. GALAPAGOS: COMPANY SNAPSHOT
TABLE 40. BIOGEN: COMPANY SNAPSHOT
TABLE 41. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
TABLE 42. PROMETIC LIFE SCIENCES INC.: COMPANY SNAPSHOT
TABLE 43. CIPLA INC.: COMPANY SNAPSHOT

LIST OF FIGURES

FIGURE 1. IDIOPATHIC PULMONARY FIBROSIS MARKET SEGMENTATION
FIGURE 2. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION, (20142016)
FIGURE 3. TOP WINNING STRATEGIES: NATURE AND TYPE
FIGURE 4. TOP WINNING STRATEGIES: NATURE AND COMPANY
FIGURE 5. TOP INVESTMENT POCKETS
FIGURE 6. MARKET SHARE ANALYSIS, 2016
FIGURE 7. IMPACT ANALYSIS, 2016